Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPK7 | Q13164 | 10/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607070 | 0.90 | MAPK7 (0.63) | POLBMAPK7MAPK14PKMDOT1L | |
| SCHEMBL17607056 | 0.90 | POLB (0.60) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL31114409 | 0.90 | MAPK7 (0.63) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL299630 | 0.85 | POLB (0.50) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL1507426 | 0.84 | MAPK14 (0.59) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL17607058 | 0.84 | MAPK14 (0.67) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL30874562 | 0.84 | RAB9A (0.52) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL29190944 | 0.84 | RAB9A (0.52) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL298212 | 0.82 | POLB (0.51) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 | |
| SCHEMBL1507329 | 0.82 | MAPK7 (0.48) | POLBMAPK7MAPK14RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | CANCER RESEARCH TECH LTD (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| EP-3194390-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 | Cancer Research Technology Ltd (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042341-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2427452-A1 | P38 KINASE INHIBITING AGENTS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
| EP-2300485-B1 | PYRROLO-[2, 3-C]-PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8017605-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | SAHOO SOUMYA P | 2011-05-05 | — | — | US | disclosed |
| WO-2010129208-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | POLB 2065/4885MAPK7 4/4885MAPK14 13/4885 |
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | MAPKAPK5, MAP3K5, MAPK15 | POLB 1445/4885MAPK7 38/4885MAPK14 14/4885 |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | POLB 1822/4885MAPK7 4/4885MAPK14 13/4885 |
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | MAPKAPK5, MAP3K5, MAPK15 | POLB 1445/4885MAPK7 38/4885MAPK14 14/4885 |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | MAPK1, MAP3K8, MAPK8 | POLB 888/4885MAPK7 37/4885MAPK14 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.